Celcuity's REVTORPYK Receives Recommendation From National Comprehensive Cancer Network Clinical Practice Guidelines In Oncology As Preferred Category 1 Second-Line Therapy
Celcuity Inc CELC
$86.38
▼ -1.44%
($-1.26)
🔥 High Short Interest
🗓️ Earnings Next Week
Open
$88.50
Prev Close
$87.64
Day Range
$85.46 – $88.50
52W Range
$38.00 – $151.02
Market Cap
$4.21B
Beta
0.20
EPS (TTM)
$-3.90
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2017-09-20 |
| Shares Out. | 48,770,000 |
| Website | celcuity.com/ ↗ |
| Phone | 13026587581 |
| Employees | 155 |
| Net Income | -$52.8M |
| Free Cash Flow | -$172.9M |
| Total Assets | $410.2M |
| Total Liabilities | $356.6M |
| Equity | $53.5M |
About Celcuity Inc
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Celcuity Inc is a publicly traded company under the ticker symbol CELC on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-07-01)